MedTrace Logo

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

NCT03397862 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2018-09-14

No results posted yet for this study

Summary

A study to assess the skin irritation and sensitization potential of Corplex™ Donepezil Transdermal Delivery System (TDS)

Conditions

  • Skin Irritation
  • Sensitization

Interventions

DRUG

Donepezil TDS

Donepezil patch

DRUG

Vehicle TDS

Placebo patch

Sponsors & Collaborators

  • Corium, Inc.

    lead INDUSTRY

Principal Investigators

  • Danielle Armas, MD, CPI · Celerion

  • Laura Sterling, MD, MPH · Celerion

  • Vaeling Miller · Corium International

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-14
Primary Completion
2018-03-08
Completion
2018-04-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03397862 on ClinicalTrials.gov